So far, the development of targeted therapies was mostly fueled by knowledge related to primary tumor biology and, currently, around one dozen therapeutic antibodies and 28 different inhibitors are in clinical application, targeting essentially the tumor antigens HER2, EGFR, EpCAM, BRAF and VEGF [2–5]. This evidence concerns the gene ERBB2 and neoplasm.